Our patents, patent applications and continued research relate to an analogue of Substance P, which is a structural derivative that contains different amino acids compared to the parent compound.This analogue, which we have termed Homspera, is the basis for our research and development of potential drug candidates. Substance P is found in the body and performs a large number of actions, including modulation of the immune system and stimulation of hematopoieisis (blood cell formation). To date, we refer to two derivatives of Homspera that we have named Radilex and Viprovex. Although these contain the identical active ingredient as Homspera, we have adopted different nomenclarture due to the potential difference in formulations and indications for use.
Our current focus is to develop Homspera for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells. It is the belief of our Mmanagement that the stem cell activity exhibited by Homspera underlies some of the effects previously reported in potential applications like treatment for radiation exposure and infectious disease using Homspera derivatives Radilex and Viprovex, respectively, which are described below. Recent studies have evaluated the effects of Homspera on human adult stem cell activity. Additionally, ongoing studies are being performed to evaluate the efficacy of Homspera as a potential product to increase the healing rate of wounds. Our goals include developing these potential drug candidates to be used as possible countermeasures for homeland security threats, including radiological, chemical and biological agents, and to meet the commercial need for beneficial effects in conditions such as radiation therapy, influenza, anthrax and potentially other microbial ailments. We have discovered activities of Homspera that may potentially open additional commercialization opportunities in areas such as human adult stem cell stimulation, vaccine adjuvants, which stimulate the immune system above that of a stand-alone vaccine, and wound healing.
We are researching Radilex for use as a potential treatment for acute exposure to radiation. We believe that Radilex, if developed, may be an acceptable candidate to be marketed to governmental agencies for procurement. Further, we believe that a commercial market may exist for the use of Radilex as it relates to the treatment of radiation-induced side effects of cancer treatments, either as a stand-alone treatment or as a co-therapeutic agent to be used with other therapies. Viprovex is being researched by us for use in potential treatments of exposure to bacillus biological agents, such as infectious organisms, which currently include influenza virus and anthrax. We believe that Viprovex, if developed, can be used in potential applications for sale to governments for the treatment of exposure to anthrax and pandemic influenza. In addition, we believe that potential commercial opportunities may exist for the treatment of seasonal influenza and other viral or bacterial infections, either as a stand-alone drug or as an adjuvant to other existing drugs. Based on early studies on Homspera and existing literature on Substance P, we are also researching the efficacy of Viprovex as a potential treatment for exposure to chemical agents, such as formalin. Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|||||||||||||||||||||||||||||||||||||||||||
